B
ITCI

Bailard’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bailard’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,480
Closed -$1.07M – 829
2024
Q1 		$1.07M Sell
15,480
-1,600
-9% -$110K 0.03% 295
2023
Q4 		$1.22M Buy
17,080
+200
+1% +$11.5K 0.04% 264
2023
Q3 		$879K Hold
16,880
– – 0.03% 288
2023
Q2 		$1.07M Buy
16,880
+1,400
+9% +$87.2K 0.04% 264
2023
Q1 		$838K Sell
15,480
-14,600
-49% -$706K 0.03% 294
2022
Q4 		$1.59M Sell
30,080
-2,100
-7% -$105K 0.06% 212
2022
Q3 		$1.5M Hold
32,180
– – 0.06% 211
2022
Q2 		$1.84M Hold
32,180
– – 0.07% 192
2022
Q1 		$1.97M Hold
32,180
– – 0.07% 209
2021
Q4 		$1.68M Sell
32,180
-126,000
-80% -$5.29M 0.05% 214
2021
Q3 		$5.9M Sell
158,180
-13,520
-8% -$470K 0.2% 108
2021
Q2 		$7.01M Hold
171,700
– – 0.24% 97
2021
Q1 		$5.83M Buy
171,700
+400
+0.2% +$13.9K 0.22% 99
2020
Q4 		$5.45M Buy
171,300
+39,300
+30% +$1.03M 0.25% 85
2020
Q3 		$3.39M Sell
132,000
-9,000
-6% -$205K 0.18% 109
2020
Q2 		$3.62M Buy
+141,000
New +$2.85M 0.2% 95

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bailard's ITCI Position: Q2 2024 in Review

Bailard sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 15,480 shares — an estimated $1.07M sold.

Bailard first reported a position in ITCI in Q2 2020 and held it in 16 quarters. The position peaked at $7.01M in Q2 2021. 376 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

  • Bailard reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
  • Bailard sold 15,480 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $1.07M.
  • Bailard first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 16 quarters.
  • Bailard's Intra-Cellular Therapies Inc. position peaked at $7.01M in Q2 2021.
  • 376 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on Bailard's 13F filing for Q2 2024, filed 25 Jul 2024.